The global drug-induced dyskinesia market is expected to be worth USD 399.8 Million in the fiscal year 2023, which rose up from USD 382 Million in the fiscal year 2022. From 2023 to 2033, the global market is expected to grow at a steady 4.25% CAGR, reaching a value of USD 620.2 Million by the end of 2033.
Drug-induced dyskinesia is an uncommon neurological condition caused by the long-term use of antipsychotic medicines that act on dopamine receptors. Due to a number of factors, including a rise in the incidence of drug-induced dyskinesia, a greater number of unmet therapeutic interventions, and the anticipated introduction of several pipeline drugs, it is predicted that the market for drugs used to treat drug-induced dyskinesia will experience significant market expansion over the course of the forecast period.
Despite the many medications used to treat drug-induced dyskinesia, the US FDA has only given its approval to Deutetrabenazine and Valbenazine so far. Other medications are also used to treat the symptoms of drug-induced dyskinesia, including botulinum toxin, benzodiazepines, dopamine-depleting medicines, amantadine, and calcium channel blockers, among others.
Drug-induced dyskinesia causes uncontrollable or spontaneous movements such as twitching, thrusting, and grimacing. Even though a disease may last a lifetime, early treatment can stop symptoms from getting worse and, in many circumstances, even reverse them. Drug-induced dyskinesia may be minor, moderate, or severe, depending on the symptoms. In light to moderate cases of drug-induced dyskinesia, the face, lips, tongue, and jaw muscles are tense and jerking; typical actions include smacking, blinking, or puckering lips, and thrusting the tongue out. People with mild signs of drug-induced dyskinesia frequently experience uncontrollable movement in their arms and legs. Hence, at present, various manufacturers are aimed at developing drugs and other solutions that would cure the symptoms of this disease and prevent the person from getting it again.
| Attributes | Details |
|---|---|
| Anticipated Base Year Value (2022) | USD 382 Million |
| Expected Market Value (2023) | USD 399.8 Million |
| Projected Forecast Value (2033) | USD 620.2 Million |
| Global Growth Rate (2023 to 2033) | 4.25% |
| CAGR of North America (2023) | 4.3% |
| CAGR of APAC (2023 to 2033) | 3.5% |
| Prominent Players in The Global Market | Teva Pharmaceuticals; Neurocrine Bioscience; Sun Pharmaceutical Industries Ltd; SteriMax Inc.; Lannett Co Inc; Adamas Pharmaceuticals, Inc; Sanis; AbbVie Inc.; Dystonia Medical Research Foundation; Pharos: Illuminating the Druggable ; Genome |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global drug-induced dyskinesia market grew at a CAGR of 3.1% from 2017 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence. Due to the growing frequency of drug-induced dyskinesia linked to an increased incidence of neurologic diseases such as schizophrenia, bipolar disorder, and Alzheimer's disease, the worldwide market for drug-induced dyskinesia is anticipated to post a consistent revenue CAGR in 2021.
Additionally, rising Research and Development efforts, elevated awareness, technical advancements, a robust product pipeline, a desire for more potent therapies, and innovation in treatment are predicted to drive market expansion throughout the course of the projection period.
Such factors are expected to boost the global sales of drug-induced dyskinesia solutions. As a result, the global drug-induced dyskinesia market is expected to forecast a CAGR of over 4% from 2023 to 2033.
Increasing cases of schizophrenic as well as other neurological diseases to boost the demand
Dyskinesia has been proven to be much more prevalent among patients who suffer from diseases like schizophrenia and other neurological disorders. Patients with schizophrenia who use antipsychotic medications for a prolonged period of time have a substantial risk of developing drug-induced dyskinesia. As a result, an increasing number of antipsychotic medications come with a significant risk, which encourages the market's expansion. For instance, according to a report from the World Health Organization published in January 2022, schizophrenia affects 24 million people worldwide, or 0.32%, out of which a ratio of 1 in 222 people (0.45%) were adults.
Additionally, according to figures released by the World Health Organization (WHO) in October 2021, 1 in 6 individuals throughout the world will be 60 years of age or older by 2030, increasing the likelihood that they may acquire Parkinson's and Alzheimer's disease. Thus, it is anticipated that the pool demographic for drug-induced dyskinesia would increase as Alzheimer's disease prevalence rises, increasing the demand for treatment and potentially stimulating the market. Such factors are sure to propel the market for drug-induced dyskinesia during the forecast period.
Various neuroleptic drugs cause dyskinesia among the patients
Long-term neuroleptic medication usage raises the likelihood of drug-induced dyskinesia and hence boosts the market for drug-induced dyskinesia medicines. When used for a few weeks or longer, specific medications that disrupt dopamine receptors within the brain can result in drug-induced dyskinesia. Antipsychotics, antiemetics, and antidepressants are some of these medications.
Schizophrenia is treated with typical antipsychotic medications, commonly referred to as first-generation antipsychotic medications. Some of these medications also address other disorders including nausea and vomiting. However, when used over an extended length of time, these medications cause dyskinesia in the patients.
Since a side effect of neuroleptic medications is drug-induced dyskinesia, the frequency of neurological conditions including Alzheimer's disease, schizophrenia, and bipolar disorder is rising, and so is the need for antipsychotic medications.
Such factors are expected to accelerate the demand for drug-induced dyskinesia during the forecast period.
Principal Consultant
Clonidine-induced hypotension and other relevant factors will impede the growth
The market for medications that produce drug-induced dyskinesia is anticipated to suffer from adverse effects such as clonidine-induced hypotension as well as sedation. These elements are recognized to lessen patients' dyskinesia symptoms as well as effectively treat their illnesses for an extended length of time.
The market is also anticipated to be hampered by high treatment costs, poor diagnosis rates, societal stigma, a shortage of qualified healthcare professionals, and the relatively high price of a clinical trial over the projection period.
High prevalence of neuropathic diseases to boost the regional demand
North America is predicted to hold the dominant market share of 41% revenue share in 2023 and is the fastest-growing market for drug-induced dyskinesia, with a dominant 4.3% CAGR from 2023 to 2033.
A large portion of the global market for drug-induced dyskinesia treatments is anticipated to be accounted for by North America, owing to factors such as an aging population, a higher incidence of schizophrenia, rising dyskinesia awareness, rising healthcare costs, and developed healthcare infrastructure. As the world's population ages, various neurological illnesses will emerge, necessitating the use of antipsychiatric medications. As a result, these groups are more likely to get certain illnesses. In May 2021, the National Alliance on Mental Health reported that 1.5 million Americans, or 0.25% to 0.64% of the population, were living with schizophrenia.
Thus, the high prevalence of the condition among the elderly population of nations across North America is expected to increase demand for the development of therapeutic medications, resulting in the market's expansion. A further factor supporting the growth of the drug-induced dyskinesia treatment market in this area is the association of this illness with specific patient pools such as individuals treated for schizophrenia as well as bipolar disorder in this area.
Large patient pool and more research and awareness programs to propel the sales
During the forecast period, the APAC market for drug-induced dyskinesia is expected to garner a steady CAGR of 3.5%. But at the time, this market is presently acquiring a 31% market share in the global drug-induced dyskinesia market.
Due to a larger patient pool, more involvement in research and public awareness campaigns about drug-induced dyskinesia therapy, and enhanced public health awareness, the Asia Pacific area is anticipated to develop at the quickest rate throughout the projection period.
The drug-induced dyskinesia APAC market is also anticipated to develop throughout the projected period as a result of an expanding patient base for neuroleptic illnesses including bipolar disorder, schizophrenia, and others as well as improved healthcare infrastructure and greater healthcare spending.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The VMAT 2 segment will gain the dominant market share
Over the course of the forecast period, the VMAT 2 segment by drug class is anticipated to occupy a significant share of the global drug-induced dyskinesia market. In 2023, this category is anticipated to dominate with a 46% revenue share.
VMAT2 inhibitors are drugs that produce dopamine depletion in nerve endings and are employed to treat chorea caused by neurodegenerative disorders (like Huntington's chorea) or dyskinesias caused by neuroleptic medicines. With more neurological disorders and more people being prescribed antipsychotic medications, VMAT is predicted to have healthy development in the next few years. According to the research article Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future released in February 2022, there are an estimated 6.1 million people worldwide who have Parkinson's disease. The prevalence rises with age, reaching 1% to 3% in people over 65.
Additionally, according to figures released by the World Health Organization (WHO) in October 2021, 1 in 6 persons worldwide would be 60 years of age or older by the year 2030. Parkinson's therapy is linked to drug-induced dyskinesia, and it is anticipated that the prevalence of the illness would increase during the projection period, increasing demand for the possible treatment and driving segment growth. Such factors are expected to accelerate the growth prospects for drug-induced dyskinesia from 2023 to 2033.
The hospital's segment will become more significant from 2023 to 2033
On the basis of the sales channel, the most dominant segment is the hospital segment, which is expected to occupy a global market share of 32% from 2023 to 2033.
The hospital segment is expected to acquire the dominant position on the basis of channel type. This can be attributed to the increasing number of elderly patients admitted to hospitals. When it comes to the elderly, no one wants to take risks and keep the patient at home, particularly in case of any neurological disorder. In hospitals, the patients can be monitored effectively 24X7 and given the medicines at the apt time they need. Hence, with such advantages, the segment is expected to witness immense growth during the forecast period.
The new companies are aimed at developing their products with enhanced safety features and new technology to make the products stand out in the global market.
Some of the prominent players in the global market for drug-induced dyskinesia are:
Some of the prominent developments of the key players in the market are:
During the historical period of 2017 to 2022, the drug-induced dyskinesia market grew at a CAGR of 3.1%.
The global drug-induced dyskinesia market is predicted to rise with a steady 4.25% CAGR from 2023 to 2033.
The global drug-induced dyskinesia market is currently worth more than USD 382 Million.
By 2033, the global drug-induced dyskinesia market is projected to reach a market size of USD 620.2 Million.
In 2023, the VMAT 2 segment by drug class type is anticipated to dominate with a 46% revenue share.
The hospitals segment by end user will occupy the second largest segment during the forecast period with a 32% market share in 2023.
The North American region is predicted to grow with a steady CAGR of 4.3% from 2023 to 2033.
The APAC drug-induced dyskinesia market is expected to grow with a steady CAGR of 3.5% from 2023 to 2033.
1. Executive Summary | Drug-Induced Dyskinesia Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Dopamine-Depleting Medications 5.2. VMAT2 Inhibitors 5.3. GABA Receptor Agonist Medications 5.4. Anticholinergic Medications 6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User 6.1. Hospitals 6.2. Clinics 6.3. Others 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. South Asia & Pacific 7.5. East Asia 7.6. Middle East and Africa (MEA) 8. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 11. South Asia & Pacific Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 12. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 13. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 14. Key Countries Market Analysis 15. Market Structure Analysis 16. Competition Analysis 16.1. Neurocrine Biosciences, Inc 16.2. Teva Pharmaceutical Industries Ltd 16.3. Sun Pharmaceutical Industries Ltd 16.4. SteriMax Inc. 16.5. Lannett Co Inc 16.6. Adamas Pharmaceuticals, Inc 16.7. Sanis 16.8. AbbVie Inc. 16.9. Dystonia Medical Research Foundation 16.10. Pharos: Illuminating the Druggable Genome 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Drug-Induced Dyskinesia Market
